Literature DB >> 25280227

Genomic alterations as mediators of miRNA dysregulation in ovarian cancer.

Casina W S Kan1, Viive M Howell, Michael A Hahn, Deborah J Marsh.   

Abstract

Ovarian cancer is the fifth most common cause of cancer death in women worldwide. Serous epithelial ovarian cancer (SEOC) is the most common and aggressive histological subtype. Widespread genomic alterations go hand-in-hand with aberrant DNA damage signaling and are a hallmark of high-grade SEOC. MicroRNAs (miRNAs) are a class of small noncoding RNA molecules that are nonrandomly distributed in the genome. They are frequently located in chromosomal regions susceptible to copy number variation (CNV) associated with malignancy that can influence their expression. Widespread changes in miRNA expression have been reported in multiple cancer types including ovarian cancer. This review examines CNV and single nucleotide polymorphisms, two common types of genomic alterations that occur in ovarian cancer, in the context of their influence on the expression of miRNA and the ability of miRNA to bind to and regulate their target genes. This includes genes encoding proteins involved in DNA repair and the maintenance of genomic stability. Improved understanding of mechanisms of miRNA dysregulation and the role of miRNA in ovarian cancer will provide further insight into the pathogenesis and treatment of this disease.
© 2014 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25280227     DOI: 10.1002/gcc.22221

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  9 in total

Review 1.  Emerging diagnostic, prognostic and therapeutic biomarkers for ovarian cancer.

Authors:  Khalid El Bairi; Abdul Hafeez Kandhro; Adel Gouri; Wafaa Mahfoud; Noureddine Louanjli; Brahim Saadani; Said Afqir; Mariam Amrani
Journal:  Cell Oncol (Dordr)       Date:  2016-12-15       Impact factor: 6.730

2.  Expression of microRNA-30a-5p in drug-resistant and drug-sensitive ovarian cancer cell lines.

Authors:  Jin Liu; Xiaohua Wu; Hongmei Liu; Yijuan Liang; Xinping Gao; Zhihui Cai; Weiming Wang; Hui Zhang
Journal:  Oncol Lett       Date:  2016-07-08       Impact factor: 2.967

3.  High copy number variation of cancer-related microRNA genes and frequent amplification of DICER1 and DROSHA in lung cancer.

Authors:  Karol Czubak; Marzena Anna Lewandowska; Katarzyna Klonowska; Krzysztof Roszkowski; Janusz Kowalewski; Marek Figlerowicz; Piotr Kozlowski
Journal:  Oncotarget       Date:  2015-09-15

4.  Genomic imbalances are involved in miR-30c and let-7a deregulation in ovarian tumors: implications for HMGA2 expression.

Authors:  Antonio Agostini; Marta Brunetti; Ben Davidson; Claes G Tropé; Sverre Heim; Ioannis Panagopoulos; Francesca Micci
Journal:  Oncotarget       Date:  2017-03-28

5.  Identification and Characterization of MicroRNAs Associated with Somatic Copy Number Alterations in Cancer.

Authors:  Jihee Soh; Hyejin Cho; Chan-Hun Choi; Hyunju Lee
Journal:  Cancers (Basel)       Date:  2018-11-29       Impact factor: 6.639

Review 6.  Deregulated miRNA clusters in ovarian cancer: Imperative implications in personalized medicine.

Authors:  Amoolya Kandettu; Divya Adiga; Vasudha Devi; Padmanaban S Suresh; Sanjiban Chakrabarty; Raghu Radhakrishnan; Shama Prasada Kabekkodu
Journal:  Genes Dis       Date:  2022-03-01

7.  DROSHA rs642321 Polymorphism Influence Susceptibility to Childhood Acute Lymphoblastic Leukemia: A Preliminary Report.

Authors:  Mohammad Hashemi; Seyed-Shahaboddin Hasani; Majid Naderi
Journal:  Indian J Med Paediatr Oncol       Date:  2017 Oct-Dec

Review 8.  Ancient and modern: hints of a core post-transcriptional network driving chemotherapy resistance in ovarian cancer.

Authors:  Sarah Blagden; Mai Abdel Mouti; James Chettle
Journal:  Wiley Interdiscip Rev RNA       Date:  2017-08-01       Impact factor: 9.957

9.  MicroRNA-378a-3p contributes to ovarian cancer progression through downregulating PDIA4.

Authors:  Yao Chanjiao; Chen Chunyan; Qiu Xiaoxin; Han Youjian
Journal:  Immun Inflamm Dis       Date:  2020-11-07
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.